In the United States, about 15 million Americans have food allergies; one in every 13 children has this potentially deadly condition. A food allergy reaction sends a patient to the emergency department every three minutes, totaling over 200,000 visits per year. Epinephrine is the first-line treatment for severe or life-threatening allergic reactions, or anaphylaxis. Anaphylaxis is a sudden, severe, rapidly progressive, and potentially life-threatening allergic reaction that affects multiple organ systems of the body at the same time. Anaphylaxis requires immediate medical attention, as it can be fatal if not reversed within seconds or minutes of coming in contact with the allergen.
In recent years, a growing number of states have adopted epinephrine entity stocking laws. These laws allow authorized entities like restaurants and sports venues to obtain and store auto-injectable epinephrine, or EpiPens, and administer the drug to individuals experiencing anaphylaxis.
This issue brief provides an overview of key components of epinephrine entity stocking laws.
This accompanying resource a surveys states’ epinephrine entity stocking laws.